特許の崖という業界の常識と戦う塩野義製薬

「開発10年超は当たり前、特許の崖といった業界の常識と戦う塩野義製薬の経営戦略　目指すは創薬型企業からHaaS企業へのトランスフォーム」という2月10日付けの記事を読みました。特許の崖で苦しんでいる製薬業界ですが、なるほどと思います。
Felo AIのDeep Researchで会社全体を、OpenAIのDeep ResearchとGemini Deep Researchで成長戦略への知的財産部門の貢献実績を、調べました。
出来栄えは、各自ご判断ください。
 
開発10年超は当たり前、特許の崖といった業界の常識と戦う塩野義製薬の経営戦略
目指すは創薬型企業からHaaS企業へのトランスフォーム
2025.2.10
https://jbpress.ismedia.jp/articles/jir-print/86330
 
 
Shionogi’s Battle Against the Industry Norm of the “Patent Cliff”
 
I read an article dated February 10 titled "Shionogi’s Business Strategy: Fighting Against the Industry Norm of a 10+ Year Development Cycle and the Patent Cliff—Aiming to Transform from a Drug Discovery Company to an HaaS Company." The pharmaceutical industry has long struggled with the patent cliff, and I found the article quite insightful.
Using Felo AI’s Deep Research, I examined the company as a whole, while OpenAI’s Deep Research and Gemini Deep Research were used to investigate the intellectual property department's contributions to its growth strategy.
I’ll leave the evaluation of the results up to each individual.
 
Shionogi’s Business Strategy: Fighting Against the Industry Norm of a 10+ Year Development Cycle and the Patent Cliff
Aiming to Transform from a Drug Discovery Company to an HaaS Company
February 10, 2025
Link to the article
 

Your browser does not support viewing this document. Click here to download the document.

Your browser does not support viewing this document. Click here to download the document.

Your browser does not support viewing this document. Click here to download the document.